Results 91 to 100 of about 21,646 (232)

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

Health and Quality of Life Outcomes, 2017
Background Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource ...
Shannon L. Reynolds, Sameer R. Ghate, Richard Sheer, Pranav K. Gandhi, Chad Moretz, Cheng Wang, Stephen Sander, Mary E. Costantino, Srinivas Annavarapu, George Andrews   +9 more
doaj   +1 more source

A Comprehensive Disproportionality Analysis of Drug‐Related Head Injury Reports Using the FAERS Database

Brain and Behavior, Volume 16, Issue 6, June 2026.
ABSTRACT Objective This study aimed to identify and characterize drugs associated with reports of head injury through a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database. Methods A retrospective disproportionality analysis was conducted on FAERS reports from 2004 to 2023.
Jiaqi Guo, Luming Wei, Junfeng Liu, Jimei Zhang, He Wang, Wanjun Lu   +5 more
wiley   +1 more source

PERANAN IDARUCIZUMAB UNTUK MENETRALISIR EFEK ANTIKOAGULAN DABIGATRAN

, 2019
Latar Belakang: Dabigatran etexilate (Pradaxa) telah disetujui oleh FDA dan Uni Eropa sebagai antikoagulan untuk mencegah stroke dan emboli sistemik pada pasien dengan atrial fibrilasi non-valvular dan satu atau lebih faktor risiko lain.
Soejitno, Andreas, Putra, Ida Bagus Kusuma   +1 more
core   +1 more source

Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.

PLoS ONE, 2016
BackgroundDabigatran was proven to have similar effect on the prevention of recurrence of venous thromboembolism (VTE) and a lower risk of bleeding compared to vitamin K antagonists (VKA). The aim of this study is to assess the cost-effectiveness (CE) of
J Stevanović, L A de Jong, B S Kappelhoff, E P Dvortsin, M Voorhaar, M J Postma   +5 more
doaj   +1 more source

Induction of cytochrome P450 2C9 and P‐glycoprotein activity by antiseizure medications: A systematic review and network meta‐analysis

Epileptic Disorders, Volume 28, Issue 3, Page 855-867, June 2026.
Abstract Objectives Antiseizure medications (ASMs) can induce the activity of drug‐metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P‐glycoprotein (P‐gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P‐gp substrates.
Hagar Cohen, Nahawand Bahash, Tomer Ben‐Shushan, Ilan Matok, Sara Eyal   +4 more
wiley   +1 more source

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination

, 2018
Idarucizumab, a humanized monoclonal antibody fragment (Fab), provides rapid and sustained reversal of dabigatran-mediated anticoagulation. Idarucizumab and dabigatran are mainly eliminated via the kidneys.
Markus Honickel, Joanne Van Ryn, Grottke, Oliver, Moschetti, Viktoria, Reilly, Paul, Honickel, Markus, Guanfa Gan, Gan, Guanfa, Viktoria Moschetti, Stephan Glund, Oliver Grottke, Glund, Stephan, Paul Reilly, van Ryn, Joanne   +13 more
core   +1 more source

Dabigatran must be used carefully: literature review and recommendations for management of adverse events

, 2019
Shan Lin,* Yan Wang,* Lei Zhang, Wei GuanDepartment of Respiratory Medicine, Qinghai University Affiliated Hospital, Xining 810001, People’s Republic of China*These authors contributed equally to this workAbstract: Atrial fibrillation increases the
Lin S, Guan W, Zhang L, Wang Y
core  

Dabigatran Use Associated with Hemopericardium and Hemothorax

, 2020
Concurrent spontaneous hemopericardium and hemothorax due to anticoagulant use are extremely rare in clinical practice. Dabigatran is an oral direct thrombin inhibitor approved to prevent stroke or thromboembolic episodes in patients with nonvalvular ...
Josip Katić, Jure Mirat, Avelini Perković, Ružica, Ružica Avelini Perković, Marko Skelin, Katić, Ana, Dario Rahelić, Katić, Josip, Skelin, Marko, Ana Katić, Rahelić, Dario, Mirat, Jure, Katić, Karla, Karla Katić   +13 more
core   +1 more source

Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation

Pharmaceuticals, 2012
Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients.
Josef Finsterer, Claudia Stöllberger
doaj   +1 more source

Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation

Journal of the Formosan Medical Association, 2019
Background/purpose: Dabigatran is effective in preventing ischemic stroke and systemic embolism in patients with atrial fibrillation. Although the therapeutic window for dabigatran is wide, its pharmacokinetic properties can differ between specific ...
Shin-Yi Lin, Sung-Chun Tang, Ching-Hua Kuo, Li-Kai Tsai, Shin-Joe Yeh, Li-Jiuan Shen, Jiann-Shing Jeng   +6 more
doaj   +1 more source